N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD

Respiration

Volumn 66, Issue 6, 1999, Pages 495-500

  Pela, R ^a   Calcagni, A M ^b   Subiaco, S ^c   Isidori, P ^d   Tubaldi, A ^e   Sanguinetti, C M ^a,f  

^a Presidio Ospedaliero Unificato A   (Italy)

^b ASL 11   (Italy)

^c Ospedale di Jesi   (Italy)

^d Azienda Ospedaliera Ospedale   (Italy)

^e Ospedale di Macerata   (Italy)

^f NONE   (Italy)

Author keywords

Chronic obstructive pulmonary disease; Drug dosage; Exacerbations; N actylcysteine

Indexed keywords

ACETYLCYSTEINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERANCE; EPIGASTRIC PAIN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032759974     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029447     Document Type: Article

References (23)

1. American Thoracic Society: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152(suppl):77-120.
2. Siafakas NM, Vermeire P, Pride NB, et al: Optimal assessment and management of chronic obstructive pulmonary disease. Eur Respir J 1995;8:1398-1420.
3. Maier KL, Leuschel L, Constabel U: Increased oxidised methionine residues in BAL fluid proteins in acute or chronic bronchitis. Eur Respir J 1992;5:651-658.
4. Dekhuijzen PNR, Aben KKH, Dekker I, et al: Increased exhalation of hydrogen peroxide in patients with stable and unstable COPD. Am J Respir Crit Care Med 1996;154:813-816.
5. Grassi C, Morandini GC: A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol 1976;9:393-396.
6. Multicenter Study Group: Long-term oral acetylcysteine in chronic bronchitis: A double-blind controlled study. Eur J Clin Respir Dis 1980;61(suppl 111):93:108.
7. Boman G, Backer U, Larsson S, Melander B, Wahlander L: Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: Report of a trial organised by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 1983;64: 405-415.
8. Jackson M, Barnes J, Cooksey P: Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: A double-blind placebo-controlled study: J Med Res 1984; 198-205.
9. British Thoracic Society Research Committee: Oral N-acetylcysteine and exacerbation rates with chronic bronchitis and severe airway obstruction. Thorax 1985;40:832-835.
10. Meister R: Langzeittherapie mit Acetylcystein Retard-Tabletten bei Patienten mit chronischer Bronchitis: Eine doppelblinde placebo-kontrollierte Studie. Forum Prakt Allg Arzt 1986;25:18-22.
11. Parr GD, Huitson A: Oral Fabrol (oral N-acetylcysteine) in chronic bronchitis. Br J Dis Chest 1987;81:341-348.
12. Rasmussen JB, Glennon C: Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J 1988;1: 351-355.
13. Hansen NCG, Skriver A, Bronsen-Riis L, et al: Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 1994;88:531-535.
14. Lundbäck B, Lindström M, Andersson S, Nyström L, Rosenhall L, Stjerberg N: Possible effect of acetylcysteine on lung function. Eur Respir J 1992;5(suppl 15):289.
15. Quanjer PH: Standardised lung function testing: Report Working Party standardisation of Lung Function tests' of the European Respiratory Society and the European Community for Coal and Steel. Eur Respir J 1993;6(suppl 16): 1-100.
16. Moldeus P, Cotgreave IA, Berggren M: Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 1986;50:31-42.
17. Rogers DF, Jeffery PK: Inhibiton by oral N-acetylcysteine of cigarette smoke-induced 'bronchitis' in the rat. Exp Lung Res 1986;10: 267-283.
18. Bridges RB: Protective action of thiols on neutrophil function. Eur J Respir Dis 1985;66 (suppl 139):40-48.
19. Voisin C, Aerts C, Fournier E, Firlik M: Acute effects of tobacco smoke on alveolar macrophages cultured in gas phase. Eur J Respir Dis 1985;66(suppl 139):76-81.
20. Borregaard N, Jensen HS, Bjerrum OW: Prevention of tissue damage: Inhibition of myeloperoxidase mediated inactivation of alpha 1-proteinase inhibitor by N-acetylcysteine, glutathione, and methionine. Agents Actions 1987; 22:255-260.
21. Riise GC, Larsson S, Larsson P, Jeansson S, Andersson BA: The intrabronchial microbial flora in chronic bronchitis patients: A target for N-acetylcysteine therapy? Eur Respir J 1994;7: 94-101.
22. De Flora S, Grassi C, Carati L: Attenuation of influenza symptomatology and improvement of immunological parameters due to long-term treatment with N-acetylcysteine. Eur Respir J 1997;10:1535-1541.
23. Murphy TF, Sethi S: Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;146:1067-1083.